TL;DR
This meta-analysis systematically reviewed 15 studies to assess the efficacy and safety of tirofiban as an adjunct to endovascular therapy (EVT) for acute ischemic stroke. The findings suggest tirofiban improves outcomes in anterior circulation strokes and enhances recanalization in posterior circulation strokes, while also reducing mortality without increasing bleeding risk, indicating its potential as a safe and effective treatment.
What Problem Does This Paper Address?
Acute ischemic stroke (AIS) is a leading cause of death and disability. Endovascular therapy (EVT), which involves physically removing blood clots from brain arteries, has become a standard treatment, particularly for large vessel occlusions. However, the use of adjunctive medications like tirofiban (a potent antiplatelet drug) alongside EVT has been a subject of debate. While tirofiban is known to prevent platelet aggregation, concerns exist about its potential to increase the risk of bleeding, especially in the context of a damaged blood vessel after EVT. Furthermore, the effectiveness and safety of EVT, and by extension adjunctive therapies like tirofiban, might differ between strokes affecting the anterior circulation (supplying the front of the brain) and the posterior circulation (supplying the back of the brain, including the brainstem and cerebellum). This paper aims to clarify these uncertainties by systematically analyzing existing evidence.
Methods
The researchers conducted a comprehensive systematic review and meta-analysis, adhering to PRISMA guidelines. They searched major databases (PubMed, Embase, Cochrane Library, Web of Science) for relevant studies published up to March 2022. The inclusion criteria focused on cohort studies and randomized controlled trials that compared EVT with tirofiban versus EVT alone in patients with acute ischemic stroke, specifically looking at both anterior circulation stroke (ACS) and posterior circulation stroke (PCS).
Key outcomes assessed included:
- Safety: Symptomatic intracranial hemorrhage (sICH) and 3-month mortality.
- Efficacy: Good functional outcome (mRS 0-2), excellent functional outcome (mRS 0-1), and successful recanalization (mTICI ≥ 2b).
The meta-analysis employed the Mantel-Haenszel method to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analyses were performed for ACS and PCS. Quality assessment of included studies was done using the Cochrane Risk of Bias Tool for RCTs and the Newcastle-Ottawa Scale (NOS) for cohort studies.
Datasets
This paper is a meta-analysis of existing studies. It does not introduce new datasets or benchmarks. The data analyzed comprises information extracted from 15 previously published studies that met the inclusion criteria.
Key Insights and Ideas
- Differential Efficacy by Circulation: The study highlights that tirofiban's benefits vary depending on the stroke's location. It appears to improve functional outcomes in the anterior circulation but primarily enhances recanalization in the posterior circulation.
- Safety Profile: A crucial finding is that tirofiban, when used with EVT, does not significantly increase the risk of symptomatic intracranial hemorrhage, even showing a trend towards reduction in the posterior circulation. This addresses a major concern regarding its use.
- Mortality Reduction: Tirofiban consistently demonstrated a significant reduction in 3-month mortality across both anterior and posterior circulation strokes, underscoring its life-saving potential.
- Heterogeneity in Recanalization: While tirofiban improved recanalization in PCS, it did not show a significant improvement in ACS. This suggests differences in clot composition or treatment timing might play a role.
Key Results
The meta-analysis included 15 studies with a total of 4608 patients.
- Safety:
- Overall sICH: Tirofiban did not significantly increase sICH (OR = 0.97, 95% CI = 0.78–1.21, P = .35).
- ACS sICH: No significant difference (OR = 1.12, 95% CI = 0.88–1.44, P = .35).
- PCS sICH: Tirofiban significantly reduced sICH (OR = 0.60, 95% CI = 0.37–0.95, P = .03).
- Mortality:
- Overall 3-month mortality: Significantly reduced by tirofiban (OR = 0.72, 95% CI = 0.62–0.84, P < .0001).
- ACS mortality: Significantly reduced (OR = 0.80, 95% CI = 0.65–0.98, P = .03).
- PCS mortality: Significantly reduced (OR = 0.63, 95% CI = 0.50–0.80, P = .0001).
- Efficacy:
- ACS good functional outcome: Significantly improved (OR = 1.24, 95% CI = 1.06–1.45, P = .008).
- PCS recanalization rate: Significantly improved (OR = 1.94, 95% CI = 1.43–2.65, P < .0001).
- ACS recanalization rate: No significant improvement (OR = 1.17, 95% CI = 0.93–1.47, P = .17).
- PCS good functional outcome: No significant improvement (OR = 1.03, 95% CI = 0.81–1.30, P = .81).
Limitations and Future Work
The authors acknowledge several limitations:
- Variability in Administration: The included studies had different protocols for tirofiban administration (route and dose), making direct comparisons challenging.
- Prior IV Thrombolysis: The rate of prior intravenous thrombolysis varied across studies, which could influence outcomes.
- Heterogeneity: While efforts were made to address it, some heterogeneity was observed in certain analyses, suggesting potential differences in study populations or methodologies.
- Lack of High-Level Evidence for PCS: There's a scarcity of large, multicenter randomized controlled trials specifically for tirofiban in posterior circulation large artery occlusive strokes, limiting the strength of evidence for this subgroup.
Future work should focus on conducting large, multicenter randomized controlled trials to standardize tirofiban administration protocols and further elucidate its role in different stroke types and locations. Investigating the optimal timing and route of tirofiban administration would also be valuable.
Summary updated